Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| BIOGEN | 17 | 54 | -0,06 % | ||
| KALVISTA PHARMACEUTICALS | 16 | 1 | -2,28 % | ||
| REGENERON PHARMACEUTICALS | 14 | 22 | -1,12 % | ||
| AGIOS | 6 | 8 | -2,48 % | ||
| BIONTECH | 5 | 13 | -0,75 % | ||
| IONIS PHARMACEUTICALS | 5 | - | -2,00 % | ||
| APELLIS PHARMACEUTICALS | 4 | 4 | -0,97 % | ||
| GH RESEARCH | 4 | - | +4,88 % | ||
| AMGEN | 3 | 27 | -0,88 % | ||
| AUTOLUS THERAPEUTICS | 3 | - | +0,83 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08:30 | DRINGEND: Biontech: Könnte die Aktie jetzt komplett einbrechen? - Meine klare Einschätzung dazu | Hebelschein-Spekulant | |||
| 07:06 | argenx SE: argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026 | 2 | GlobeNewswire (USA) | ||
| 06:48 | Mesoblast reports Q1 results | 2 | Seeking Alpha | ||
| 03:05 | Mesoblast shares: Cash burn falls and Ryoncil sales climb | 3 | The Motley Fool Australia | ||
| 03:00 | Mesoblast Limited: Mesoblast Reports Ryoncil Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million | 36 | GlobeNewswire (Europe) | Achieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Activity Report for Quarter Ended March 31, 2026 (Appendix 4C) NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Mesoblast... ► Artikel lesen | |
| 02:27 | Why Biogen Stock Was a Winner on Wednesday | 3 | The Motley Fool | ||
| 01:27 | Why Agios Pharmaceuticals Stock Zoomed to a 13% Gain on Wednesday | 1 | The Motley Fool | ||
| 00:56 | MESOBLAST LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | - | ASX | ||
| 00:42 | Oppenheimer raises Ionis Pharmaceuticals price target on guidance | 4 | Investing.com | ||
| 00:26 | Roivant Sciences Ltd. (ROIV): David Einhorn Trims Stake | 1 | Insider Monkey | ||
| Mi | $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today | 4 | Benzinga.com | ||
| Mi | Pacira BioSciences Q1 2026 Earnings Preview | 1 | Seeking Alpha | ||
| Mi | Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know | 1 | Zacks | ||
| Mi | Truist cuts Regeneron stock price target on FDA approval delay | 5 | Investing.com | ||
| Mi | Stifel raises Ionis Pharmaceuticals price target on sHTG opportunity | 4 | Investing.com | ||
| Mi | Tarsus Pharmaceuticals, Inc: Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026 | 1 | GlobeNewswire (USA) | ||
| Mi | Autolus Therapeutics plc - 8-K, Current Report | - | SEC Filings | ||
| Mi | Autolus to cut about 13% of workforce in cost reduction initiative | 5 | Seeking Alpha | ||
| Mi | Ultragenyx vor Quartalsbericht: Wichtiger Test für die Gentherapie-Pipeline | 2 | Investing.com Deutsch | ||
| Mi | Relay Therapeutics vor Quartalszahlen: Lässt sich der klinische Erfolg in Kurspotenzial ummünzen? | 1 | Investing.com Deutsch |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.